We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
SHINGRIX (GlaxoSmithKline Australia Pty Ltd)
Product name
SHINGRIX
Date registered
Evaluation commenced
Decision date
Approval time
91 (255 working days)
Active ingredients
recombinant Varicella Zoster Virus glycoprotein E antigen
Registration type
EOI
Indication
SHINGRIX (powder and suspension for injection) is now also indicated for the prevention of herpes zoster (HZ) and post-herpetic neuralgia use in adults 18 years of age or older at increased risk of HZ.